3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
15
Nivolumab
9
atezolizumab
5
Ipilimumab
4
Drug Therapy
4
Docetaxel
4
Radiotherapy
3
Radiosurgery
3
Paclitaxel
3
Gemcitabine
3
Cetuximab
3
Carboplatin
3
Blood Specimen Collection
3
temsirolimus
2
spartalizumab
2
sargramostim
2
motexafin gadolinium
2
liposomal doxorubicin
2
entinostat
2
durvalumab
2
belinostat
2
Sirolimus
2
Psychiatric Rehabilitation
2
Peripheral Blood Stem Cell Transplantation
2
Metformin
2
Irinotecan
2
Fluorouracil
2
Etoposide
2
Dexamethasone
2
Cyclophosphamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Interleukin-15
×
Thoracic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled